Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

Stock Information for Conduit Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
Conduit Pharmaceuticals Announces Leadership Changes
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.